Early research (Phase 1)Study completedNCT01276717What this trial is testingStudy of Carfilzomib and Vorinostat for Relapsed or Refractory LymphomaWho this might be right forLymphoma University of Rochester 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07622784What this trial is testingPirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell LymphomaWho this might be right forRelapsed or Refractory B-cell Lymphoma Sun Yat-sen University 20
Testing effectiveness (Phase 2)Study completedNCT00078858What this trial is testingMycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+132 more Fred Hutchinson Cancer Center 37
Early research (Phase 1)UnknownNCT05039658What this trial is testingEfficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)Who this might be right forDLBCL Innovent Biologics (Suzhou) Co. Ltd. 50
Testing effectiveness (Phase 2)Study completedNCT00002908What this trial is testingBryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaWho this might be right forLeukemiaLymphoma Barbara Ann Karmanos Cancer Institute
Early research (Phase 1)Study completedNCT03019666What this trial is testingPh I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLWho this might be right forMultiple MyelomaNon-Hodgkin LymphomaDiffuse Large B Cell Lymphoma+5 more Masonic Cancer Center, University of Minnesota 39
Testing effectiveness (Phase 2)UnknownNCT02981745What this trial is testingStudy of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaWho this might be right forRelapsed or Refractory B Cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaWaldenstrom's Macroglobulinemia+3 more Centaurus Biopharma Co., Ltd. 200
Testing effectiveness (Phase 2)Ended earlyNCT01278615What this trial is testingSelumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaWho this might be right forRecurrent Adult Diffuse Large Cell Lymphoma National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Ended earlyNCT00851552What this trial is testingBortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentWho this might be right forLymphoma Roswell Park Cancer Institute 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149What this trial is testingAcalabrutinib + Liso-Cel In R/R Aggressive B-Cell LymphomasWho this might be right forRefractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more Patrick C. Johnson, MD 28
Early research (Phase 1)UnknownNCT03060850What this trial is testingA Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLWho this might be right forB-cell Lymphoma Hangzhou ACEA Pharmaceutical Research Co., Ltd. 184
Testing effectiveness (Phase 2)Study completedNCT02674750What this trial is testingStudy to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsWho this might be right forRelapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations Curis, Inc. 70
Testing effectiveness (Phase 2)Study completedNCT00436618What this trial is testingEverolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentWho this might be right forLeukemiaLymphomaLymphoproliferative Disorder Mayo Clinic 277
Testing effectiveness (Phase 2)Ended earlyNCT01796470What this trial is testingEntospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesWho this might be right forChronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+1 more Gilead Sciences 66
Testing effectiveness (Phase 2)Study completedNCT03610724What this trial is testingPhase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsWho this might be right forNon-Hodgkin Lymphoma Novartis Pharmaceuticals 34
Early research (Phase 1)Study completedNCT03255096What this trial is testingEvaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6Who this might be right forDiffuse Large B-cell LymphomaHigh-Grade B-cell Lymphoma Hoffmann-La Roche 39
Early research (Phase 1)Looking for participantsNCT05705570What this trial is testingClinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid MalignanciesWho this might be right forAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia RefractoryB-cell Lymphoma Recurrent+3 more Nelson Hamerschlak 30
Early research (Phase 1)Study completedNCT03340766What this trial is testingStudy Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Who this might be right forRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Amgen 31
Testing effectiveness (Phase 2)Looking for participantsNCT06534437What this trial is testingMEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)Who this might be right forNon-Hodgkin Lymphoma, B-cell Ryvu Therapeutics SA 178
Early research (Phase 1)Study completedNCT02242045What this trial is testingStudy to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)Who this might be right forChronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaFollicular Lymphoma+3 more Gilead Sciences 6